Pujol P, Rey J M, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T
Service de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, France.
Cancer Res. 1998 Dec 1;58(23):5367-73.
Although estrogen receptor (ER)-alpha is expressed in both benign and malignant ovarian tumors, the role of ER in ovarian carcinogenesis of epithelial tumors is still unknown. In view of the recent characterization of ER-beta, a second form of ER that seems to be highly expressed in ovaries, we reexamined this issue by studying the relative expression of ER-alpha and -beta in human ovarian tumor progression. We developed a competitive PCR assay based on coamplification of the two ERs in target nucleotide sequences displaying a high homology (exons 3 and 4). Coamplification experiments with varying amounts of plasmids containing ER-alpha and -beta cDNAs showed that this assay was reliable for discriminating as little as a 2-fold difference in the initial ER-alpha:ER-beta cDNA ratio. The relative expression of ER-alpha compared with ER-beta mRNAs was studied in human ovarian cancer cell lines (n = 5) and in normal ovaries (n = 6), then in human benign and malignant tumor samples including ovarian cysts (n = 24), borderline tumors (n = 3), and cancers (n = 10). In normal ovaries, ER-beta mRNA was the predominant ER form, whereas in ovarian cancer cell lines ER-alpha mRNA was markedly increased as compared with ER-beta. In benign and borderline tumors, ER-beta mRNA was detected in 78% of tumors, whereas ER-alpha mRNA was detected in 29%. In ovarian carcinomas, both ER-alpha and -beta mRNAs were expressed in 80% of tumors. The ER-alpha:ER-beta mRNA ratio was >1 in only one cyst sample (4%). In contrast, the ER-alpha:ER-beta mRNA ratio was markedly increased in ovarian cancers because 60% showed an ER-alpha:ER-beta mRNA >1. In situ hybridization experiments showed overlapping tissular distribution of ER-beta and -alpha expression in cancers and cysts, with a main localization in the epithelium and only a low level of expression in stromal cells. In summary, we found an increase in the ER-alpha:ER-beta mRNA ratio in ovarian carcinomas as compared with normal ovaries and cysts. These data suggest that overexpression of ER-alpha relative to ER-beta mRNA may be a marker of ovarian carcinogenesis.
尽管雌激素受体(ER)-α在卵巢良恶性肿瘤中均有表达,但ER在上皮性肿瘤的卵巢癌发生过程中的作用仍不清楚。鉴于最近对ER-β的特性描述,ER的第二种形式似乎在卵巢中高表达,我们通过研究ER-α和-β在人类卵巢肿瘤进展中的相对表达来重新审视这个问题。我们基于在显示高度同源性的靶核苷酸序列(外显子3和4)中对两种ER进行共扩增,开发了一种竞争性PCR检测方法。用不同量的含有ER-α和-β cDNA的质粒进行共扩增实验表明,该检测方法能够可靠地区分初始ER-α:ER-β cDNA比例低至2倍的差异。在人卵巢癌细胞系(n = 5)和正常卵巢(n = 6)中研究了ER-α与ER-β mRNA的相对表达,然后在包括卵巢囊肿(n = 24)、交界性肿瘤(n = 3)和癌症(n = 10)的人类良性和恶性肿瘤样本中进行了研究。在正常卵巢中,ER-β mRNA是主要的ER形式,而在卵巢癌细胞系中,与ER-β相比,ER-α mRNA明显增加。在良性和交界性肿瘤中,78%的肿瘤检测到ER-β mRNA,而29%的肿瘤检测到ER-α mRNA。在卵巢癌中,80%的肿瘤同时表达ER-α和-β mRNA。仅在一个囊肿样本(4%)中ER-α:ER-β mRNA比例>1。相反,卵巢癌中ER-α:ER-β mRNA比例明显增加,因为60%的病例显示ER-α:ER-β mRNA>1。原位杂交实验表明,癌症和囊肿中ER-β和-α表达的组织分布重叠,主要定位于上皮细胞,而基质细胞中的表达水平较低。总之,我们发现与正常卵巢和囊肿相比,卵巢癌中ER-α:ER-β mRNA比例增加。这些数据表明,相对于ER-β mRNA,ER-α的过表达可能是卵巢癌发生的一个标志物。